Details of the Drug

General Information of Drug (ID: DMBT3AI)

• Drug Name: Belantamab mafodotin

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Approved	[1]

• Drug Type: Antibody drug conjugate
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 4666 mgh/L [2]
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 42 mg/L [2]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 0.78 h [2]
  Clearance: The clearance of drug is 0.9 L/day [2]
  Half-life: The concentration or amount of drug in body reduced by one-half in 12 days [2]
  Metabolism: The drug is metabolized via oxidation and demethylation, however further data is not readily available [2]
  Vd: The volume of distribution (Vd) of drug is 11 L [2]
• Cross-matching ID:
  DrugBank ID: DB15719
  TTD ID: D52NZX

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-cell maturation protein (TNFRSF17)	TTZ3P4W	TNR17_HUMAN	Not Available	[1]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] FDA Approved Drug Products: Blenrep Belantamab Mafodotin-blmf Intravenous Injection
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [4] ClinicalTrials.gov (NCT04181827) A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). U.S. National Institutes of Health.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] ClinicalTrials.gov (NCT03758417) A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
• [7] ClinicalTrials.gov (NCT03448978) Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
• [8] Clinical pipeline report, company report or official report of Cartesian Therapeutics.
• [9] ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT
• [10] ClinicalTrials.gov (NCT03287804) APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma
• [11] ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
• [12] A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021 Mar 9;5(5):1291-1304.